Bifidobacterium infantis 35624: The Strain Behind Align’s IBS Trial Data

Of all the Bifidobacterium strains marketed to people with IBS, one has generated more peer-reviewed trial data than any other: Bifidobacterium infantis 35624 — the single strain inside Procter & Gamble’s Align. It’s the most-studied IBS-specific probiotic strain on the market, with a body of evidence stretching back to a landmark 2006 American Journal of Gastroenterology trial by Whorwell and colleagues. Understanding what this strain actually does — and where the limits of that research lie — matters more than the marketing on either side of the debate.

The short answer

Bifidobacterium infantis is a Bifidobacterium subspecies that has been studied more than almost any other probiotic strain in adult irritable bowel syndrome. The single strain that drives most of the clinical interest is B. infantis 35624 — the active ingredient in Procter & Gamble’s Align and the focus of the Whorwell et al. 2006 trial in The Lancet-tier journal American Journal of Gastroenterology. Strain-specific research has explored its effect on composite IBS symptom scores at roughly 1 billion CFU per day. A multi-strain formula that includes companion Bifidobacterium and Lactobacillus species offers broader microbiome coverage than a single-strain product; which approach makes sense depends on your goals and what your gastroenterologist recommends.

What is Bifidobacterium infantis?

Bifidobacterium infantis is one of the earliest microbial colonizers of the human gut. It establishes in the breastfed infant intestine within days of birth and dominates the infant colon during the first months of life, before declining as the diet broadens.

A nomenclature note that matters: in formal taxonomy, the organism is now classified as Bifidobacterium longum subsp. infantis. The shorter form “B. infantis” remains the standard usage in clinical literature and on supplement labels, but it is technically a subspecies of B. longum. Functionally, however, the two operate quite differently. B. longum persists across the lifespan; B. infantis is adapted to the infant gut and the unique sugars in breast milk.

That distinction is why both species appear in the literature with different evidence profiles. B. longum shows up in adult microbiome diversity and gut-brain research; B. infantis shows up in infant nutrition research and, separately, in a focused body of adult IBS trials anchored by the 35624 strain.

The key strain — B. infantis 35624

Most of what people mean when they say “B. infantis is studied for IBS” refers to one specific strain: B. infantis 35624 (also designated UCC35624 and marketed as Bifantis). It was originally isolated from the human gastrointestinal tract and developed at the Alimentary Pharmabiotic Centre at University College Cork before being licensed to Procter & Gamble for the Align supplement line.

Several features make 35624 the trial workhorse of the IBS probiotic literature:

• A long publication trail in IBS contexts dating to the early 2000s.
• A defined, well-characterized clinical dose (1×10⁹ CFU per day).
• Mechanistic work suggesting it may modulate inflammatory cytokine signaling at the gut interface.
• A single-source commercial supply chain (one branded strain, one quality lineage), which makes the published evidence directly attributable to a specific product.

That last point cuts both ways. Strain-specific research only applies to that strain. The 2014 ISAPP consensus on probiotics is explicit: benefits demonstrated for one strain cannot be assumed to extend to other strains, even within the same species or subspecies. A generic “B. infantis” on a supplement label, with no strain identifier, tells you nothing about whether the published 35624 evidence applies.

The evidence base — trial by trial

The published research on B. infantis 35624 in IBS is unusually deep for a single strain. The following studies are the ones cited most frequently when clinicians discuss the strain.

Whorwell et al. 2006 — the foundational trial

Published in the American Journal of Gastroenterology, this study enrolled 362 women with IBS in a randomized, placebo-controlled trial of B. infantis 35624 at three doses (1×10⁶, 1×10⁸, and 1×10¹⁰ CFU/day) versus placebo for four weeks. The 1×10⁸ CFU dose was associated with improvement in a composite IBS symptom score covering abdominal pain, bloating, and bowel difficulty, with effects observed across IBS subtypes. The 10¹⁰ dose did not outperform 10⁸, and in some measures performed worse — an early signal that more CFU is not always better. This trial is the reason 10⁹ CFU/day became the de facto standard dose for the strain.

O’Mahony et al. 2005 — the head-to-head with L. salivarius

An earlier study in Gastroenterology compared B. infantis 35624 with Lactobacillus salivarius UCC4331 and placebo over eight weeks in 77 IBS patients. B. infantis 35624 was associated with greater symptom improvement than either comparator. The paper also reported changes in peripheral blood mononuclear cell cytokine profiles, providing some of the earliest mechanistic data linking the strain to immune signaling at the systemic level.

Charbonneau et al. 2013 — the supplement-formulation work

A four-week study in Gut Microbes evaluated B. infantis 35624 in the encapsulated commercial formulation used in Align. It reinforced the 1 billion CFU/day dose as the clinically meaningful target and is one of the references cited on the Align product literature itself.

Quigley 2018 — the review of reviews

Eamonn Quigley, one of the longest-active researchers in probiotic gastroenterology, summarized the state of probiotic evidence in IBS in Current Opinion in Gastroenterology. B. infantis 35624 features as one of the better-evidenced single-strain options, with the caveat that effect sizes in IBS remain modest, placebo response in IBS trials is unusually high (often 30–40%), and heterogeneity across studies limits how clean any aggregate signal can be.

Salem & Roland 2017 — an IBS-D focused look

A clinical review focused on diarrhea-predominant IBS placed B. infantis 35624 alongside Saccharomyces boulardii, L. plantarum 299v, and L. rhamnosus GG as the strains with the most relevant evidence in the IBS-D subtype. The review reinforced strain specificity as the central principle of probiotic selection.

Dosing — what the trials actually used

The dose that ran through the Whorwell 2006 trial as efficacious — and that became the standard for nearly all subsequent B. infantis 35624 research — is 1×10⁹ CFU per day. One billion CFU. Notably, this is on the lower end of what most multi-strain probiotic products contain per capsule (many sit in the 10–50 billion CFU range across multiple strains).

A few practical implications:

• Mega-dose products with 100+ billion CFU are not delivering more of the published B. infantis 35624 evidence. The trial dose is 1 billion.
• The Whorwell trial’s 10¹⁰ arm performed worse than 10⁸ in some measures, suggesting that for this strain, higher is not better.
• Multi-strain formulas typically declare total CFU across all strains. The per-strain count for any individual organism may be a fraction of that total, which is usually fine — the goal is microbial diversity, not single-strain saturation.
• Strain shelf stability matters. B. infantis is anaerobic and relatively fragile; encapsulation, moisture barriers, and (in some formulations) refrigeration affect the live count actually delivered.

Daily dosing for at least four weeks is the minimum trial window in most of the literature. Eight to twelve weeks is a more honest evaluation period for IBS symptoms in general.

B. infantis vs. other Bifidobacterium species

Three Bifidobacterium species dominate the probiotic supplement world. They are related but functionally distinct.

• B. longum — the long-resident colon dweller. Studied for fermentation, short-chain fatty acid production, and microbial diversity across the lifespan. Common in daily-maintenance multi-strain formulas.
• B. lactis — the most-studied Bifidobacterium for transit regularity and stool consistency. The BB-12 strain has hundreds of clinical citations in its own right.
• B. infantis — the IBS-anchored strain in adult research and the dominant breastfed-infant colonizer in pediatric research. Taxonomically a subspecies of B. longum, but with a distinct ecological niche and a distinct clinical evidence profile.

A complete probiotic typically does not need to include all three at high doses. A practical multi-strain design pairs a regularity-focused Bifidobacterium (often B. lactis) with a diversity-focused Bifidobacterium (often B. longum) and Lactobacillus partners studied in functional gut contexts. Whether to add a dedicated B. infantis 35624 product on top depends on whether single-strain Align-style supplementation is something your clinician has specifically suggested.

Safety and tolerability

B. infantis has a long safety record in both adult and infant research. It is one of the native colonizers of the healthy human gut and has Generally Recognized as Safe (GRAS) status when used in commercial supplement and infant formula applications. The 35624 strain specifically has been used in published adult IBS trials with no significant adverse event signals at clinical doses.

Standard probiotic cautions still apply. People who are severely immunocompromised, who have central venous catheters, or who are in critical-care settings should not start any probiotic without their treating physician’s involvement — rare cases of probiotic bacteremia have been documented in these populations across multiple strains. Most healthy outpatient adults tolerate B. infantis well; mild gas or bloating in the first week of any new probiotic is common and usually transient.

Infant applications — the HMO connection

The other major research arc for B. infantis sits outside IBS and inside infant nutrition. B. infantis is uniquely adapted to metabolize human milk oligosaccharides (HMOs) — the complex sugars in breast milk that have no nutritional value to the infant but feed the colonizing microbiome. Most Bifidobacterium strains cannot fully utilize the HMO pool; B. infantis can.

The Frese et al. 2017 study in mSphere examined activated B. infantis EVC001 supplementation in breastfed infants and showed durable colonization and shifts in stool microbiome and metabolite profiles consistent with the strain’s HMO-utilizing biology. EVC001 is a separate, infant-targeted strain (not 35624) and is the active organism in pediatric products such as Evivo. The adult-IBS evidence for B. infantis 35624 does not transfer to infant applications, and vice versa — the strains, the populations, and the outcomes are all different.

For families exploring infant probiotics, this is a conversation for the pediatrician. The strain choice, the form (drops vs. powder), and the rationale all depend on the specific infant context (breastfed vs. formula-fed, full-term vs. preterm, antibiotic history) and should not be selected from a supplement aisle alone.

Who might benefit most

People who are most likely to find B. infantis-focused supplementation worth discussing with a clinician include:

• Adults with diagnosed IBS who have completed (or are working through) a structured low-FODMAP trial with a registered dietitian and want to layer in an evidence-backed probiotic.
• People who have been recommended Align by a gastroenterologist and want to understand what the underlying strain actually is.
• People who have tried generic multi-strain probiotics without benefit and want to test a single-strain product with a defined trial dose, on the recommendation of their provider.
• People comparing multi-strain formulas and looking specifically for the inclusion of well-characterized Bifidobacterium species.

It is worth being honest about who is less likely to benefit. B. infantis 35624 has not been shown to treat IBS, eliminate symptoms, or substitute for the dietary and clinical care that current IBS guideline-based management recommends. Effect sizes in the published trials are modest, the placebo response in IBS is high, and individual response varies considerably. A reasonable framing is that it’s one well-evidenced option to test alongside the other layers of a clinician-led plan — not a destination.

The bottom line

Bifidobacterium infantis 35624 is the single most-studied probiotic strain in adult IBS research, with a published trail anchored by Whorwell 2006 and reinforced by O’Mahony 2005, Charbonneau 2013, and Quigley’s 2018 review. At its trial dose of 1 billion CFU/day, it is associated with improvement on composite IBS symptom scores across subtypes. It is also the active strain in Align — one strain, one product. Strain-specific research has explored its use in IBS; it has not established that it treats the condition. A multi-strain formula that pairs B. longum, B. lactis, and Lactobacillus partners with a prebiotic substrate offers broader microbiome coverage; a single-strain 35624 product offers the most concentrated dose of the specific strain in the published trials. Which approach fits depends on your goals and on the gastroenterologist-led plan you are layering it into.